---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060399"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:35:09.804314+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q1 2024 net loss $3.3M; cash $3M; secures up to $19.25M financing

## Summary
- Net loss of $3.3M ($0.75 per share) vs $4.8M ($2.07) in Q1 2023; grant revenue rose to $1.7M from $0.5M.
- Cash balance $3.0M at March 31, 2024, down from $8.6M at December 31, 2023.
- Closed private placement for initial $7.25M with potential total of $19.25M from healthcare funds and insiders.
- Received $3M Department of Defense grant recommendation for Phase 1 rhenium obisbemeda trial in pediatric brain cancer.
- Acquired exclusive rights to CNSide leptomeningeal metastases diagnostic; reported positive top-line FORESEE trial data.

## SEC filing metadata
- accession: 0000950170-24-060399
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/0000950170-24-060399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/pstv-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060399
- JSON: https://secwatch.observer/filing/0000950170-24-060399.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060399.txt

## Key facts
- Earnings Releases
  PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $1.7 million in grant revenue, net income $3.3 million, EPS $(0.75) per share.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $1.7 million in grant revenue
  - Net income: $3.3 million
  - EPS: $(0.75) per share
  - Result: reported results
  source text: FIRST QUARTER 2024 FINANCIAL RESULTS • The Company’s cash balance was $3 million at March 31, 2024 compared to $8.6 million at December 31, 2023. • The Company recognized $1.7 million in grant revenue in the first quarter of 2024 compared to $0.5 million in the first quarter of 2023, which represents CPRIT’s share of the costs incurred for the Company’s rhenium ( 186 Re) obisbemeda development for the treatment of patients with LM • Total operating loss for the first quarter of 2024 was $3.3 million compared to $4.8 million in the same period of 2023. The decrease was primarily due to increased grant revenue • Net loss for first quarter of 2024 was $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, for the same period the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/0000950170-24-060399-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.